热门资讯> 正文

艾伯维完成从吉尔伽美什收购抑郁症资产布替西洛辛

2025-10-17 21:56

AbbVie (NYSE:ABBV) has completed its acquisition of depression asset bretisilocin from Gilgamesh Pharmaceuticals.
The candidate, currently in phase 2, is considered a psychedelic compound and a short-acting serotonin 5-HT_2A receptor agonist and 5-HT releaser under investigation for major depressive disorder.
In August, AbbVie said it would acquire bretisilocin for up to $1.2B.

More on AbbVie

AbbVie: Wins Accumulating While We Wait For Next BD Steps
AbbVie For Healthy Dividend Growth
AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
AbbVie ends in green after six straight sessions of declines
AbbVie could face patent battle over depression asset gained in Gilgamesh deal

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。